Press Release

Saudi Arabia Human Insulin Market to grow with a CAGR of 1.68%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Saudi Arabia Human Insulin Market.

 

According to TechSci Research report, “Saudi Arabia Human Insulin Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Saudi Arabia Human Insulin Market has valued at USD 0.31 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 1.68 % through 2028.   This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

 The aging population is a significant driver of the demand for human insulin and diabetes-related healthcare services. The risk of developing diabetes increases with age. Type 2 diabetes is more common in older adults. As the population ages, the prevalence of diabetes also rises, leading to an increased demand for diabetes management, which often includes insulin therapy. Many individuals who have diabetes develop the condition at a younger age but live with it as they grow older. This results in a longer duration of diabetes management, and in some cases, insulin becomes a necessary part of their treatment regimen. A demographic shift toward an older population is occurring in many countries, including Saudi Arabia. This shift is due to increased life expectancy and decreased birth rates. The older population represents a larger pool of potential diabetes patients. With age, individuals with diabetes are at a higher risk of developing complications such as diabetic retinopathy, neuropathy, cardiovascular diseases, and kidney problems. Managing these complications often involves intensified diabetes treatment, which may include insulin.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Saudi Arabia Human Insulin Market.”

 

In October 2022, Nawah Scientific, a prominent provider of on-demand scientific services through its cloud lab, has officially initiated its presence in the Kingdom of Saudi Arabia with a soft launch. The company aims to establish a state-of-the-art mega lab, with investments reaching into the millions of dollars, catering to the requirements of various industries, including pharmaceuticals, food, agriculture, chemicals, and oil. This expansion marks Nawah's second regional venture, following its entry into Jordan in 2021. Nawah is introducing an innovative business model in the region, empowering scientists with the capabilities of the digital age.

Supply chain disruptions pose challenges in the Saudi Arabia Human Insulin Market, as they do in many industries. Saudi Arabia may import a significant portion of its insulin and related supplies. Disruptions in the global supply chain, such as those seen during the COVID-19 pandemic, can affect the availability and timely delivery of insulin products to the local market. Supply chain disruptions can arise from transportation problems, including delays in shipping and difficulties in transporting insulin products to distribution points and healthcare facilities. These issues can affect product availability. The manufacturing of insulin relies on specific raw materials and ingredients. Disruptions in the supply of these materials, whether due to natural disasters, trade disputes, or other factors, can lead to production delays and shortages. Manufacturing plants producing insulin may face interruptions due to a variety of factors, including equipment failures, natural disasters, or labor strikes. These disruptions can limit the production of insulin. Insulin products are sensitive to temperature variations. Supply chain disruptions that result in improper storage or exposure to extreme temperatures can compromise the quality and safety of insulin products. In response to quality or safety concerns, insulin products may need to be recalled from the market. Such recalls disrupt the supply chain and can lead to product shortages.

Saudi Arabia Human Insulin Market is segmented based on Indication, Type, Products, Route of Administration, Onset Time, and by region.

Based on the Onset Time, Saudi Arabia Human Insulin Market is segmented into Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled. Long-acting human insulin is a type of insulin medication designed to provide a steady and prolonged release of insulin into the bloodstream over an extended period. It is primarily used in the management of diabetes, specifically for maintaining baseline or "basal" insulin levels between meals and during periods of fasting. Long-acting insulin serves as a basal insulin, which means it is intended to provide a consistent level of insulin in the body to keep blood sugar (glucose) levels stable between meals and overnight when individuals are not eating. It helps prevent excessive rises in blood sugar during these times. Long-acting insulin is formulated to have a slow and steady release profile. It is designed to be absorbed gradually into the bloodstream, offering extended coverage over an extended duration. Long-acting insulin has a more prolonged duration of action, typically lasting from 18 to 24 hours. Some formulations may provide even longer coverage, up to 36 hours, depending on the specific product. Depending on the specific type and brand of long-acting insulin, it may be administered once daily or, in some cases, twice daily. The choice of dosing frequency is determined by the individual's diabetes management plan, healthcare provider's recommendations, and their unique insulin requirements.

Based on Region, Northern & Central region held the largest share in the Saudi Arabia Human Insulin Market. Northern and Central regions may have a higher concentration of healthcare professionals, including endocrinologists and diabetologists, who play a crucial role in diabetes management and insulin prescription. Government healthcare initiatives and policies may focus on these regions to address healthcare challenges, including diabetes. Subsidies, access to insulin, and diabetes management programs may be more readily available in these areas. Pharmaceutical companies and healthcare providers may choose to focus their marketing and distribution efforts in regions with higher population density and healthcare infrastructure.

 

Some of the major companies operating in the Saudi Arabia Human Insulin Market include:

  • Novo Nordisk Saudi Arabia
  • Sanofi Saudi Arabia
  • Baxter International Saudi Arabia
  • B Braun Saudi Arabia
  • Eli Lilly, and Company Saudi Arabia
  • Pfizer Saudi Arabia

 

Download Free Sample Report

Customers can also request 10% free customization on this report.

 

“Certain areas, particularly in North America, are projected to exert significant demand for Human Insulin. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Saudi Arabia Human Insulin Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Saudi Arabia Human Insulin Market by Indication (Type I Diabetes, Type Il Diabetes), By Route of Administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Saudi Arabia Human Insulin Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Saudi Arabia Human Insulin Market.

 

Contact Us-

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News